Table 3. Essential and categorical agreement rates by applying CLSI and EUCAST breakpoints against S. aureus and CoNS.
| Specie | S. aureus | CoNS | |||||||||||||||||||
| Guideline | CLSIa | EUCASTb | CLSIa | EUCASTb | |||||||||||||||||
| Antimicrobial | Categorical Agreement | Minor Errors | Major Errors | Very Major Errors | Categorical Agreement | Minor Errors | Major Errors | Very Major Errors | Categorical Agreement | Minor Errors | Major Errors | Very Major Errors | Categorical Agreement | Minor Errors | Major Errors | Very Major Errors | |||||
| M.I.C.E. | Vancomycin | 68.0% | 30.0% | 2.0% | 0% | 68.0% | - | 32.0% | 0% | 98.0% | 2.0% | 0% | 0% | 98.0% | - | 2.0% | 0% | ||||
| Teicoplanin | 100% | 0% | 0% | 0,0% | 68.0% | - | 28.0% | 4.0% | 74.0% | 24.0% | 0% | 2% | 80.0% | - | 14.0% | 6.0% | |||||
| Linezolid | 96.0% | 0% | 0% | 4.0% | 96.0% | - | 0% | 4.0% | 100% | 0% | 0% | 0% | 100% | - | 0% | 0% | |||||
| Etest | Vancomycin | 98.0% | 2.0% | 0% | 0% | 98.0% | - | 2.0% | 0% | 94.0% | 6.0% | 0% | 0% | 98.0% | - | 2.0% | 0% | ||||
| Teicoplanin | 100% | 0% | 0% | 0% | 62.0% | - | 34.0% | 4.0% | 76.0% | 22.0% | 2% | 0% | 72.0% | - | 22.0% | 6.0% | |||||
| Linezolid | 96.0% | 0% | 0% | 4.0% | 96.0% | - | 0% | 4.0% | 100% | 0% | 0% | 0% | 100% | - | 0% | 0% | |||||
| Susceptibility profile | S% | I% | R% | S% | I% | R% | S% | I% | R% | S% | I% | R% | |||||||||
| Vancomycin | 100% | 0% | 0% | 100% | - | 0% | 100% | 0% | 0% | 100% | - | 0% | |||||||||
| Teicoplanin | 100% | 0% | 0% | 96% | - | 4% | 72% | 12% | 16% | 58% | - | 42% | |||||||||
| Linezolid | 96% | 0% | 4% | 96% | - | 4% | 100% | 0% | 0% | 100% | - | 0% | |||||||||
CLSI, Clinical Laboratory Standards Institute. Breakpoints: Vancomicyn: S. aureus S≤2, I 4-8, R≥16, CoNS S≤4, I 8-16, R≥32; Teicoplanin: S≤8, I 16, R≥32; Linezolid: S≤4, R≥8.
EUCAST, European Committee on Antimicrobial Susceptibility Testing. Breakpoints: Vancomicyn: S. aureus S≤2, R>2, CoNS S≤4, R>4; Teicoplanin: S. aureus S≤2, R>2, CoNS S≤4, R>4; Linezolid: S≤4, R>4.